The outcome of patients with severe head injuries treated with amantadine sulphate

Journal of Neural Transmission

Volumn 111, Issue 4, 2004, Pages 511-514

  Saniova, B ^a,c   Drobny, M ^a   Kneslova, L ^a   Minarik, M ^b  

^a Dept Anaesthiol and Intensive Med ^*  (Slovakia)

^b Faculty of Natural Sciences   (Slovakia)

^c Martinska Fakultna Nemocnica   (Slovakia)

Author keywords

Amantadine sulphate; Brain injury; Excitotoxic substances; Neurocytoprotection

Indexed keywords

AMANTADINE SULFATE;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; COMA; DISEASE SEVERITY; FEMALE; GLASGOW COMA SCALE; HEAD INJURY; HUMAN; INTENSIVE CARE; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STANDARD; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ADULT; AMANTADINE; ANTIPARKINSON AGENTS; CONSCIOUSNESS; CRANIOCEREBRAL TRAUMA; FEMALE; HUMANS; INTENSIVE CARE; MALE; RETROSPECTIVE STUDIES;

EID: 1842627674     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0112-4     Document Type: Article

References (13)

1. Brown JIM (1998) Clinical significance of CSF glutamate concentrations following severe traumatic brain injury in humans. J Neurotrauma 15: 253-263
2. Bullock R (1996) Opportunities for neuroprotective drugs in clinical management of Parkinsonism. In: PK-Merz for therapy of Parkinsonism. Merz and Co GmbH, Frankfurt, p 68
3. Chandler MC (1988) Amantadine for the agited head-injury patient. Brain Injury 2: 309-311
4. Dávalos A (1997) Duration of glutamate release after acute ischemic stroke. Stroke 28: 708-710
5. Drobny M (1997) Local immunodefects - products of oxygen radical creation. Bratisl Lek Listy 98: 204-208
6. Jörg J, Ringendahl H, Ischebeck W, Steube D, Lambert-Baumann J (2000) Amantadinsulfat-Infusion zur Behandlug von Vigilanz-und Antriebsstörungen. Nervenheilkunde 9: 521-528
7. Kugler J (1975) Die Beeinflussung von Vigilanz und Bewußtsein durch Aminoadamantansulfat. Akt Neurol 2: 43-51
8. Safar P (1993) Cerebral resuscitation after cardiac arrest: research initiatives and future directions. Ann Emerg Med 22: 324-349
9. Schiffer R (1995) Ergebnisse der Wirksamkeit von Amantadinsulfat bei Antriebsstörungen verschiedener Genese (Erfahrungsbericht). In: Vigilanz und Antriebsstörungen-Ursachen und Behandlungsstrategien. MMV Medizin Verlag GmbH, München, p 658
10. Siesjö BK (2000) Pathophysiology of cerebral ischemia. E J Anaesthesiol 17S: 6-7
11. Steube D, Görtelmeyer R (2000) Amantadinsulfat zur Vigilanzbeeinflussung bei schweren erwobenen Hirnschäden. Neurol Rehabil 6: 307-312
12. Wallnofer H, Schiller L (1974) Amoniadamantane therapy in comatose conditions. Med Welt 25: 703-706
13. Yakovlev AG, Faden I (1995) Molecular strategies in CNS injury. J Neurotrauma 12: 767-777